top of page
  • Glenn Hearson

Research to reduce asthma attacks: (MANDALA) Study

Updated: Sep 5, 2022

We are now recruiting for a new study looking into study of an investigational drug called PT027 (the “study drug”), which is a combination of budesonide and salbutamol/albuterol sulfate (BDA) given in a metered-dose inhaler (MDI) as a possible treatment for asthma symptoms. An MDI is a device that delivers a measured amount of medication as a mist that the patient can inhale.

This study-drug combination delivers 2 well-established asthma treatments. Budesonide is a well-established corticosteroid treatment that helps to reduce swelling and tightening of airways. Many patients take budesonide regularly as a “controller” medication to control chronic symptoms and prevent asthma attacks.

Salbutamol/Albuterol (also called as PT007 in this study) is a treatment that is widely used as needed for short-term treatment of asthma symptoms. It is known as a “reliever” medication. It is hoped that this investigational drug combination of both budesonide and salbutamol/albuterol will be better at preventing severe asthma attacks compared to some standard “reliever” medications.

The main purpose of this study is to learn how well the study drug works compared to salbutamol/albuterol alone in reducing the risk of having another severe asthma attack.

The study will also investigate how safe the study drug is compared to salbutamol/albuterol alone given in an MDI for asthma attacks.

The study site Principal Investigator is; Professor Tim Harrison

This study has now fully completed



bottom of page